Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events
Information source: Ministry of Science and Technology of the People´s Republic of China
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Stroke; Transient Ischemic Attack
Intervention: Clopidogrel (Drug); Placebo of clopidogrel and Asprin (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: yongjun wang Official(s) and/or principal investigator(s): Yongjun NA Wang, M.D, Principal Investigator, Affiliation: Beijing Tian Tan Hospital, Capital Medical University, Beijing, China S.Claiborne NA Johnston, M.D, Ph.D, Principal Investigator, Affiliation: Departments of Neurology, Epidemiology, University of California, San Francisco, USA
Summary
The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel
initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days
versus a 3-month regimen of ASA 75 mg/day alone on reducing the 3-month risk of any stroke
(both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom
onset in high-risk patients with TIA or minor stroke.
Clinical Details
Official title: Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Primary outcome: Percentage of patients with the 3-month new vascular events, defined as any event of the following: Any stroke (ischemic or hemorrhage)
Secondary outcome: Percentage of patients with the 3-month new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ MI/ vascular death) as a cluster and evaluated individually.Modified Rankin Scale score changes (continuous) and dichotomized at percentage with score 0-2 vs. 3-6 at 3 month follow-up Further efficacy exploratory analysis:Impairment (changes in NIHSS scores at 3 month follow-up). Further efficacy exploratory analysis:Quality of Life (EuroQol EQ-5D scale) Efficacy endpoint will also be analyzed stratified by etiological subtypes, by time randomization (< 12 hours vs. ≥ 12 hours), by qualifying event (TIA vs. minor stroke), and by age Severe bleeding incidence (GUSTO definition), including fatal bleeding and symptomatic intracranial hemorrhage. Incidence symptomatic and asymptomatic intracranial hemorrhagic events at 3 months Intracranial hemorrhage Total mortality
Detailed description:
Inclusion criteria:
1. Adult subjects (male or female ≥ 40 years)
2. Acute non-disabling ischemic stroke (NIHSS≤3 at the time of randomization) that can be
treated with study drug within 24 hours of symptoms onset. Symptom onset is defined by
the "last see normal" principle.
3. TIA (Neurological deficit attributed to focal brain ischemia, with resolution of the
deficit within 24 hours of symptom onset), that can be treated with study drug within
24 hours of symptoms onset and with moderate-to-high risk of stroke recurrence (ABCD2
score ≥ 4 at the time of randomization). Symptom onset is defined by the "last see
normal" principle.
4. Informed consent signed
Primary Efficacy Endpoint:
Percentage of patients with the 3-month new vascular events, defined as any event of the
following: Any stroke (ischemic or hemorrhage).
Eligibility
Minimum age: 40 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion criteria:
- Adult subjects (male or female≥40 years)
- Acute non-disabling ischemic stroke (NIHSS≤3 at the time of randomization) that can
be treated with study drug within 24 hours of symptoms onset. Symptom onset is
defined by the "last see normal" principle
- TIA (Neurological deficit attributed to focal brain ischemia, with resolution of the
deficit within 24 hours of symptom onset), that can be treated with study drug within
24 hours of symptoms onset and with moderate-to-high risk of stroke recurrence (ABCD2
score≥4 at the time of randomization).Symptom onset is defined by the "last see
normal" principle
- Informed consent signed
Exclusion Criteria:
- Diagnosis of hemorrhage or other pathology, such as vascular malformation, tumor,
abscess or other major non-ischemic brain disease (e. g., multiple sclerosis) on
baseline head CT or MRI
- Isolated or pure sensory symptoms (e. g., numbness), isolated visual changes, or
isolated dizziness/vertigo without evidence of acute infarction on baseline head CT
or MRI
- Modified Rankin Scale Score>2 at randomization (pre-morbid historical assessment)
- NIH Stroke Score≥4 at randomization
- Clear indication for anticoagulation(presumed cardiac source of embolus, e. g., atrial
fibrillation, prosthetic cardiac valves known or suspected endocarditis)
- Contraindication to clopidogrel or ASA
- Known allergy
- Severe renal or hepatic insufficiency
- Severe cardiac failure, asthma
- Hemostatic disorder or systemic bleeding
- History of hemostatic disorder or systemic bleeding
- History of thrombocytopenia or neutropenia
- History of drug-induced hematologic or hepatic abnormalities
- Low white blood cell (<2 x109/l) or platelet count (<100 x109/l)
- Use of thrombolysis within 24 hours prior to randomization
- History of intracranial hemorrhage
- Anticipated requirement for long-term non-study antiplatelet drugs, or NSAIDs
affecting platelet function
- Current treatment (last dose given within 10 days before randomization) with heparin
therapy or oral anti coagulation
- Gastrointestinal bleed or major surgery within 3 months
- Planned or likely revascularization (any angioplasty or vascular surgery) within the
next 3 months (if clinically indicated, vascular imaging should be performed prior to
randomization whenever possible)
- Scheduled for surgery or interventional treatment requiring study drug cessation
- Qualifying TIA or minor stroke induced by angiography or surgery
- Severe non-cardiovascular comorbidity with life expectancy < 3 months
- Women of childbearing age not practicing reliable contraception who do not have a
documented negative pregnancy test
- Currently receiving an investigational drug or device
Locations and Contacts
Beijing Tian Tan Hospital, Capital Medical University, Beijing 100050, China
Additional Information
Starting date: July 2008
Last updated: March 11, 2012
|